Verition Fund Management’s iBio IBIO Stock Holding History

Verition Fund Management’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-35	Closed	-$3K	–	2409
2022 Q3	$3K	Sell	35 -7	-17%	-$963	﹤0.01%	2966
2022 Q2	$6K	Buy	+42	New	+$6.31K	﹤0.01%	2257

Other funds holding IBIO

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Verition Fund Management's IBIO Position: Q4 2022 in Review

Verition Fund Management sold out of iBio (IBIO) in Q4 2022, closing a stake of 35 shares — an estimated $3K sold.

Verition Fund Management first reported a position in IBIO in Q2 2022 and held it in 2 quarters. The position peaked at $6K in Q2 2022. 36 funds tracked by Wall St. Rank hold IBIO as of Q4 2022.

Verition Fund Management reported no remaining iBio position as of Q4 2022 after selling out during the quarter.
Verition Fund Management sold 35 iBio shares in Q4 2022, an estimated $3K.
Verition Fund Management first reported a position in iBio in Q2 2022 and held it in 2 quarters.
Verition Fund Management's iBio position peaked at $6K in Q2 2022.
36 funds tracked by Wall St. Rank held iBio as of Q4 2022.

Based on Verition Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.